Thermo Fisher builds $40M coronavirus test tube manufacturing facility in 6 weeks

The addition to the Lenexa site brings on more than 300 full-time workers and has helped increased production to 8 million units per week. (Thermo Fisher)

To help meet the relentless demand for COVID-19 diagnostics, Thermo Fisher Scientific has stood up a new, $40 million manufacturing facility in six weeks. 

The 120,000-square-foot plant at its Lenexa, Kansas site will be dedicated to producing viral transport media, the combination of buffering solution and plastic tubes that keep swab samples viable until they can be tested in the lab for the novel coronavirus. 

Thermo Fisher was previously tapped by the U.S. government to provide large amounts of aseptic transport media, through a $381 million contract signed in May. That month, the company would ramp up production in Lenexa from 50,000 to over 1 million media-filled tubes per week.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.
Viral transport media tubes for the company's
MicroTest kits (Thermo Fisher)

"We have a proven blueprint for high-quality VTM production in Lenexa and look forward to bringing significant new capacity on line as quickly as possible to continue the necessary testing ramp-up in the U.S.," Thermo Fisher’s chairman, president and CEO, Marc Casper, said at the time.

RELATED: Thermo Fisher, WuXi and Mayo Clinic to develop open-platform COVID-19 antibody test

The company’s Lenexa site, located just outside Kansas City, previously manufactured a range of prepared media, collection and transport products, such as plates, bottles and tubes for biopharma and food laboratories. 

The latest addition, with an official ribbon-cutting held August 28, brings on more than 300 full-time workers and has since increased production to 8 million units per week, the company said.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.